2020
DOI: 10.1101/2020.06.22.165787
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Detailed phylogenetic analysis of SARS-CoV-2 reveals latent capacity to bind human ACE2 receptor

Abstract: AbstractSARS-CoV-2 is a once-in-a-century pandemic, having emerged suddenly as a highly infectious viral pathogen. Previous phylogenetic analyses show its closest known evolutionary relative to be a virus isolated from bats (RaTG13), with a common assumption that SARS-CoV-2 evolved from a zoonotic ancestor via recent genetic changes (likely in the Spike protein receptor binding domain – or RBD) that enabled it to infect humans. We used detailed phylogenetic analysis, ancestral … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 71 publications
0
1
0
Order By: Relevance
“…Furthermore, numerous pieces of evidence show that SARS-CoV-2 infection has occurred in humans for a long time or even years ago. A recent report showed the spike protein receptor binding domain (RBD) may have a high affinity for human cell targets at least since 2013[ 34 ]. Besides, the vaccine is the best way to prevent and control virus infection, however, although several candidate vaccines have been applied in clinical trials, the efficacy and safety of these vaccines still need further evaluation.…”
Section: Dynamic Monitoring Of Genomic Mutation Of Sars-cov-2 Isolatementioning
confidence: 99%
“…Furthermore, numerous pieces of evidence show that SARS-CoV-2 infection has occurred in humans for a long time or even years ago. A recent report showed the spike protein receptor binding domain (RBD) may have a high affinity for human cell targets at least since 2013[ 34 ]. Besides, the vaccine is the best way to prevent and control virus infection, however, although several candidate vaccines have been applied in clinical trials, the efficacy and safety of these vaccines still need further evaluation.…”
Section: Dynamic Monitoring Of Genomic Mutation Of Sars-cov-2 Isolatementioning
confidence: 99%